Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) CFO Daron Evans bought 10,000 shares of the firm's stock in a transaction on Wednesday, March 26th. The shares were acquired at an average price of $2.89 per share, for a total transaction of $28,900.00. Following the transaction, the chief financial officer now owns 237,900 shares in the company, valued at approximately $687,531. This represents a 4.39 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Rezolute Trading Up 0.7 %
NASDAQ:RZLT traded up $0.02 on Tuesday, hitting $2.92. The company had a trading volume of 863,155 shares, compared to its average volume of 487,683. Rezolute, Inc. has a 52 week low of $2.22 and a 52 week high of $6.19. The stock has a market capitalization of $176.76 million, a price-to-earnings ratio of -2.39 and a beta of 0.95. The firm has a 50 day moving average of $4.22 and a two-hundred day moving average of $4.73.
Rezolute (NASDAQ:RZLT - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.11. As a group, equities analysts forecast that Rezolute, Inc. will post -0.93 EPS for the current year.
Analyst Ratings Changes
Several analysts have recently issued reports on RZLT shares. HC Wainwright reissued a "buy" rating and set a $14.00 target price on shares of Rezolute in a report on Thursday, February 13th. Craig Hallum upgraded shares of Rezolute to a "strong-buy" rating in a research note on Tuesday, February 4th. JMP Securities boosted their target price on shares of Rezolute from $8.00 to $9.00 and gave the company a "market outperform" rating in a research report on Thursday, February 13th. Finally, Guggenheim reiterated a "buy" rating on shares of Rezolute in a research report on Monday, February 10th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $24.38.
Check Out Our Latest Report on Rezolute
Institutional Trading of Rezolute
Hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. boosted its position in Rezolute by 48.5% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 19,799 shares of the company's stock worth $97,000 after buying an additional 6,470 shares during the period. JPMorgan Chase & Co. acquired a new position in shares of Rezolute during the third quarter worth $42,000. Charles Schwab Investment Management Inc. grew its stake in shares of Rezolute by 65.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock worth $112,000 after purchasing an additional 9,000 shares during the last quarter. Virtu Financial LLC increased its holdings in Rezolute by 58.0% in the third quarter. Virtu Financial LLC now owns 26,026 shares of the company's stock valued at $126,000 after purchasing an additional 9,551 shares during the period. Finally, Alpine Global Management LLC bought a new position in Rezolute during the 4th quarter worth $54,000. 82.97% of the stock is currently owned by institutional investors.
About Rezolute
(
Get Free Report)
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
Featured Articles
Before you consider Rezolute, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rezolute wasn't on the list.
While Rezolute currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
